Table 2. The cross-NAb titers to JEV, DENV2 or DENV3 in human subjects vaccinated by JEV vaccines.
| Titer | JEV(PRNT90) | DENV2(PRNT50) | DENV3(PRNT50) | |||
|---|---|---|---|---|---|---|
| INV(N = 30) | LAV(N = 22) | INV(N = 30) | LAV(N = 22) | INV(N = 30) | LAV(N = 22) | |
| <1:10 | 3(10%) | 2(9.1%) | — | — | — | — |
| 1:10 | 2(6.7%) | 2(9.1%) | — | — | — | — |
| 1:20 | 4(13.3%) | 3(13.6%) | 7(23.3%) | 4(18.2%) | 1(3.3%) | 2(9.1%) |
| 1:40 | 4(13.3%) | 3(13.6%) | 15(50%) | 8(36.4%) | 21(70%) | 2(9.1%) |
| 1:80 | 8(26.7%) | 2(9.1%) | 6(20%) | 9(40.9%) | 5(16.7%) | 10(45.5%) |
| 1:160 | 4(13.3%) | 3(13.6%) | 1(3.3%) | 1(4.5%) | 0 | 4(18.2%) |
| 1:320 | — | — | 1(3.3%) | 0 | 3(10%) | 4(18.2%) |
| >1:320 | 5(16.7%) | 7(31.8%) | — | — | — | — |
| GMTa | — | — | 1:40 | 1:40 | 1:54 | 1:97 |
| Pb | — | P > 0.05 | P < 0.05 | |||
aGMT geometric mean titer.
bP values were obtained by ANOVA when comparing the cross-NAb titers between INV and LAV groups. P values of <0.05 were considered to be significant.